CNS & Neurological Disorders - Drug Targets
Title:Meet Our Editorial Board Member
Volume: 18 Issue: 1
Author(s): Vincenzo Di Marzo
Affiliation:
Export Options
About this article
Cite this article as:
Di Marzo Vincenzo , Meet Our Editorial Board Member, CNS & Neurological Disorders - Drug Targets 2019; 18 (1) . https://dx.doi.org/10.2174/187152731801181220123311
DOI https://dx.doi.org/10.2174/187152731801181220123311 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structure Based Drug Design of Angiotensin-I Converting Enzyme Inhibitors
Current Medicinal Chemistry Peripheral Immune Signatures in Alzheimer Disease
Current Alzheimer Research The Role of Platelet/Lymphocyte Serotonin Transporter in Depression and Beyond
Current Drug Targets Pleiotropic Actions of PPARg Activators Thiazolidinediones in Cardiovascular Diseases
Current Pharmaceutical Design Does Physician Continuity Within a Clinical Trial Increase Retention and Compliance Among Adolescent Smokers?
Adolescent Psychiatry Current Advances in Anti-Influenza Therapy
Current Medicinal Chemistry Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Experimental and Clinical Application of Plasmid DNA in the Field of Central Nervous Diseases
Current Gene Therapy Human Brain Nicotinic Receptors, their Distribution and Participation in Neuropsychiatric Disorders
Current Drug Targets - CNS & Neurological Disorders Brain Inflammation, Cholesterol, and Glutamate as Interconnected Participants in the Pathology of Alzheimers Disease
Current Pharmaceutical Design Discovery of New Small Molecules and Targets Towards Angiogenesis Via Chemical Genomics Approach
Current Drug Targets Apoptosis: A Potential Therapeutic Target for Retinal Degenerations
Current Neurovascular Research Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process
Current Drug Metabolism Late Life Depression: A Diagnostic and Pharmacological Review
Current Psychopharmacology Targeting Heme Oxygenase-1 for Neuroprotection and Neuroinflammation in Neurodegenerative Diseases
Current Drug Targets Epidermal Cell Proliferation in Calorie-Restricted Aging Rats
Current Aging Science Cardiac Aging and Insulin Resistance: Could Insulin/Insulin-Like Growth Factor (IGF) Signaling be used as a Therapeutic Target?
Current Pharmaceutical Design Interferon: Cellular Executioner or White Knight?
Current Medicinal Chemistry Mesenchymal Stem Cells of Dental Origin-Their Potential for Antiinflammatory and Regenerative Actions in Brain and Gut Damage
Current Neuropharmacology Stress, Depression and Antidepressant Treatment Options in Patients Suffering from Multiple Sclerosis
Current Pharmaceutical Design